Response to: 'Correspondence on 'Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial'' by Satis et al

Research output: Contribution to journalLetterpeer-review

1 Citation (Scopus)
Original languageEnglish
Pages (from-to)E257
JournalAnnals of the Rheumatic Diseases
Volume81
Issue number12
DOIs
Publication statusPublished - 28 Sept 2020

Keywords

  • biological therapy
  • familial Mediterranean fever
  • health care
  • outcome assessment

Cite this